

Masakazu Toi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7893746/publications.pdf>

Version: 2024-02-01

165
papers

8,842
citations

126708

33
h-index

48187

88
g-index

172
all docs

172
docs citations

172
times ranked

8135
citing authors

#	ARTICLE	IF	CITATIONS
1	Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Breast Cancer</i> , 2022, 29, 174-184.	1.3	10
2	Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. <i>Breast Cancer</i> , 2022, 29, 1-8.	1.3	6
3	Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an <i>ad hoc</i> analysis of the JBCRG-C06 Safari study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 545-553.	0.6	4
4	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 438-448.	0.8	35
5	Clinical Significance of <i>PIK3CA</i> and <i>ESR1</i> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. <i>Clinical Cancer Research</i> , 2022, 28, 1500-1506.	3.2	35
6	Abstract P5-13-36: Germline <i>BRCA</i>1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022, 82, P5-13-36-P5-13-36.	0.4	0
7	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. <i>Cancer Research</i> , 2022, 82, PD2-04-PD2-04.	0.4	0
8	Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels. <i>Cancer Management and Research</i> , 2022, Volume 14, 1179-1194.	0.9	8
9	Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. <i>European Journal of Cancer</i> , 2022, 166, 185-201.	1.3	13
10	Oncobiology and treatment of breast cancer in young women. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 749-770.	2.7	11
11	Three-dimensional visualization of thoracodorsal artery perforators using photoacoustic imaging. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 3166-3173.	0.5	3
12	Abstract 6085: Clonal evolution of mammary epithelial cells into breast cancers. <i>Cancer Research</i> , 2022, 82, 6085-6085.	0.4	0
13	Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	1.7	8
14	Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. <i>Breast Cancer</i> , 2021, 28, 145-160.	1.3	7
15	Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 817-830.	2.0	10
16	Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase III clinical trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 117-131.	1.1	10
17	Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. <i>Breast Cancer</i> , 2021, 28, 1038-1050.	1.3	10
18	Supplementation with Fermented Barley Extract Prevents Mammary Epithelial Cell Invasion in an Early Breast Cancer Model. <i>Acta Histochemica Et Cytochemica</i> , 2021, 54, 73-78.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). <i>International Journal of Clinical Oncology</i> , 2021, 26, 1229-1236.	1.0	3
20	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2 ⁺ advanced breast cancer: MONARCH 2 & 3 trials. <i>Cancer Science</i> , 2021, 112, 2381-2392.	1.7	15
21	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171
22	Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1026-1026.	0.8	1
23	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. <i>Journal of Clinical Oncology</i> , 2021, 39, 518-518.	0.8	2
24	Reply to K. Hashimoto and A. Shimomura. <i>Journal of Clinical Oncology</i> , 2021, 39, 1507-1508.	0.8	0
25	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
26	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer [®] The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	0.8	153
27	Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. <i>Cancer Science</i> , 2021, 112, 3338-3348.	1.7	3
28	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. <i>Npj Breast Cancer</i> , 2021, 7, 80.	2.3	31
29	Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. <i>Breast Cancer Research</i> , 2021, 23, 87.	2.2	21
30	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2 ⁺ -Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5801-5809.	3.2	3
31	Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). <i>Cancers</i> , 2021, 13, 4008.	1.7	3
32	A Novel Real-time Navigation System for Lymphaticovenular Anastomosis Using Projection Mapping with Indocyanine Green Fluorescence. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2021, 9, e3758.	0.3	1
33	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
34	Next-Generation Clinical Trials and Research with Successful Collaborations. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 613-622.	0.8	0
35	Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 417-428.	1.1	20
36	Palbociclib as an early-line treatment for Japanese patients with hormone receptor ⁺ positive/human epidermal growth factor receptor 2 ⁺ negative advanced breast cancer: a review of clinical trial and real-world data. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2179-2193.	1.0	4

#	ARTICLE	IF	CITATIONS
37	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2. <i>JAMA Oncology</i> , 2020, 6, 116.	3.4	572
38	Preoperative vascular mapping for anterolateral thigh flap surgeries: A clinical trial of photoacoustic tomography imaging. <i>Microsurgery</i> , 2020, 40, 324-330.	0.6	23
39	Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. <i>Oncologist</i> , 2020, 25, e243-e251.	1.9	45
40	Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 882-894.	1.9	27
41	Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. <i>Breast Cancer</i> , 2020, 27, 389-398.	1.3	6
42	High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 245-257.	2.9	27
43	Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 3-11.	0.6	7
44	DNA damage repair functions and targeted treatment in breast cancer. <i>Breast Cancer</i> , 2020, 27, 355-362.	1.3	15
45	Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. <i>Communications Biology</i> , 2020, 3, 578.	2.0	20
46	Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 154-157.	1.0	6
47	Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. <i>Cancer & Metabolism</i> , 2020, 8, 13.	2.4	11
48	Is there disparity between regions and facilities in surgical resident training in Japan? Insights from a national survey. <i>Surgery Today</i> , 2020, 50, 1585-1593.	0.7	2
49	Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. <i>Cancer Medicine</i> , 2020, 9, 9246-9255.	1.3	2
50	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
51	Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR +, HER2- Advanced Breast Cancer. <i>Oncologist</i> , 2020, 25, e1346-e1354.	1.9	28
52	Neoadjuvant treatment for HER2-positive breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 32-32.	0.4	44
53	Are graduating residents sufficiently competent? Results of a national gap analysis survey of program directors and graduating residents in Japan. <i>Surgery Today</i> , 2020, 50, 995-1001.	0.7	7
54	Estrogen Induces Mammary Ductal Dysplasia via the Upregulation of Myc Expression in a DNA-Repair-Deficient Condition. <i>IScience</i> , 2020, 23, 100821.	1.9	9

#	ARTICLE	IF	CITATIONS
55	A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel+carboplatin+trastuzumab+pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Research and Treatment, 2020, 180, 135-146.	1.1	26
56	TDP2 suppresses genomic instability induced by androgens in the epithelial cells of prostate glands. Genes To Cells, 2020, 25, 450-465.	0.5	7
57	Advances in EGFR/HER2-directed clinical research on breast cancer. Advances in Cancer Research, 2020, 147, 375-428.	1.9	8
58	MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.. Journal of Clinical Oncology, 2020, 38, 1061-1061.	0.8	2
59	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology, 2020, 38, 500-500.	0.8	20
60	The long-lasting anti-tumor activity of cisplatin affecting the sustainable systemic immune alteration may improve distant-disease free survival of triple-negative breast cancer in patients with a substantial residual tumor following preoperative chemotherapy: A retrospective analysis with translational research.. Journal of Clinical Oncology, 2020, 38, e12631-e12631.	0.8	0
61	Predicting the efficacy of nivolumab combined with radiation therapy by longitudinal liquid biopsy with artificial intelligence for patients with metastatic breast cancer (translational research of the Tj ETQq1 1 0.78431 4 rgBT/Overlook	0.8	0
62	Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.. Journal of Clinical Oncology, 2020, 38, 532-532.	0.8	0
63	International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1).. Journal of Clinical Oncology, 2020, 38, 1025-1025.	0.8	1
64	SL-2 Breast cancer treatment system. Neuro-Oncology Advances, 2020, 2, ii1-ii1.	0.4	0
65	The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a ≥ 5 mm margin treated without boost irradiation. Radiation Oncology, 2019, 14, 121.	1.2	6
66	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2+ positive advanced breast cancer: Final results from MARIANNE. Cancer, 2019, 125, 3974-3984.	2.0	67
67	In silico analysis-based identification of the target residue of integrin $\alpha 6$ for metastasis inhibition of basal-like breast cancer. Genes To Cells, 2019, 24, 596-607.	0.5	3
68	Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor+ breast cancer: A multicenter, open-label, phase II study. Cancer Medicine, 2019, 8, 5468-5481.	1.3	4
69	Efficacy of Scalp Cooling in Preventing and Recovering From Chemotherapy-Induced Alopecia in Breast Cancer Patients: The HOPE Study. Frontiers in Oncology, 2019, 9, 733.	1.3	22
70	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer, 2019, 5, 5.	2.3	352
71	Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. Breast Cancer: Basic and Clinical Research, 2019, 13, 117822341882513.	0.6	1
72	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine + pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer, 2019, 19, 517.	1.1	42

#	ARTICLE	IF	CITATIONS
73	A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. <i>Surgery Today</i> , 2019, 49, 870-876.	0.7	11
74	Insights Into Breast Cancer in the East vs the West. <i>JAMA Oncology</i> , 2019, 5, 1489.	3.4	90
75	Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. <i>International Journal of Molecular Sciences</i> , 2019, 20, 984.	1.8	16
76	Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. <i>ESMO Open</i> , 2019, 4, e000476.	2.0	17
77	Digital artery deformation on movement of the proximal interphalangeal joint. <i>Journal of Hand Surgery: European Volume</i> , 2019, 44, 187-195.	0.5	4
78	Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. <i>Breast Cancer</i> , 2019, 26, 282-289.	1.3	17
79	Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 274-287.	1.0	43
80	Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase III study. <i>Cancer Science</i> , 2018, 109, 803-813.	1.7	29
81	The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. <i>European Radiology</i> , 2018, 28, 3194-3203.	2.3	7
82	Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. <i>Journal of Biological Chemistry</i> , 2018, 293, 6556-6564.	1.6	23
83	5-Chloro-2,4-dihydropyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. <i>Cancer Medicine</i> , 2018, 7, 463-470.	1.3	3
84	Expansion of human $\gamma\delta$ T cells for adoptive immunotherapy using a bisphosphonate prodrug. <i>Cancer Science</i> , 2018, 109, 587-599.	1.7	40
85	SALL4-KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. <i>Cancer Medicine</i> , 2018, 7, 454-462.	1.3	31
86	Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. <i>ESMO Open</i> , 2018, 3, e000314.	2.0	15
87	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	3.2	15
88	Abemaciclib for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 517-524.	0.9	17
89	Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 141-148.	3.0	97
90	Intravoxel Incoherent Motion and Quantitative Non-Gaussian Diffusion MR Imaging: Evaluation of the Diagnostic and Prognostic Value of Several Markers of Malignant and Benign Breast Lesions. <i>Radiology</i> , 2018, 287, 432-441.	3.6	93

#	ARTICLE	IF	CITATIONS
91	Factors associated with prolonged time to treatment failure with fulvestrant 500mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study. <i>Current Medical Research and Opinion</i> , 2018, 34, 49-54.	0.9	8
92	Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells. <i>Oncology Letters</i> , 2018, 17, 1153-1159.	0.8	3
93	Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. <i>Tumor Biology</i> , 2018, 40, 101042831881102.	0.8	5
94	BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10642-E10651.	3.3	75
95	Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. <i>Scientific Reports</i> , 2018, 8, 14930.	1.6	62
96	Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. <i>Photoacoustics</i> , 2018, 11, 6-13.	4.4	28
97	Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. <i>International Journal of Cancer</i> , 2018, 143, 2905-2918.	2.3	28
98	Development and clinical translation of photoacoustic mammography. <i>Biomedical Engineering Letters</i> , 2018, 8, 157-165.	2.1	18
99	A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): therapeutic efficacy and clinical implications of circulating endothelial cells. <i>Cancer Medicine</i> , 2018, 7, 2442-2451.	1.3	10
100	Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. <i>Cancer Medicine</i> , 2018, 7, 3044-3056.	1.3	10
101	Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1002-1002.	0.8	13
102	Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1048-1048.	0.8	2
103	Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1049-1049.	0.8	8
104	The association of early toxicity and outcomes for patients treated with abemaciclib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1053-1053.	0.8	7
105	Real-time 3D Photoacoustic Visualization System with a Wide Field of View for Imaging Human Limbs. <i>F1000Research</i> , 2018, 7, 1813.	0.8	52
106	Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 37216-37228.	0.8	24
107	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. <i>Breast Cancer</i> , 2017, 24, 111-120.	1.3	21
108	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-148.	0.8	327

#	ARTICLE	IF	CITATIONS
109	Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1131-1142.	2.0	5
110	The Sal-like 4 - integrin $\alpha 6 \beta 1$ network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 76-88.	1.9	19
111	Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. <i>New England Journal of Medicine</i> , 2017, 376, 2147-2159.	13.9	1,228
112	Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. <i>Scientific Reports</i> , 2017, 7, 5987.	1.6	49
113	A phase I pharmacokinetics/pharmacodynamics study of irinotecan combined with S ¹ for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the Tj ETQq11130.78434 rgBT (O		
114	Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. <i>Breast Cancer Research</i> , 2017, 19, 47.	2.2	19
115	Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. <i>International Journal of Clinical Oncology</i> , 2017, 22, 11-17.	1.0	90
116	Antitumor immunity and advances in cancer immunotherapy. <i>Breast Cancer</i> , 2017, 24, 1-2.	1.3	10
117	Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast. <i>Frontiers in Oncology</i> , 2017, 7, 192.	1.3	25
118	Analysis of the microvascular morphology and hemodynamics of breast cancer in mice using Spring-8 synchrotron radiation microangiography. <i>Journal of Synchrotron Radiation</i> , 2017, 24, 1039-1047.	1.0	7
119	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2 ⁻ Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2875-2884.	0.8	1,105
120	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3638-3646.	0.8	1,099
121	MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1000-1000.	0.8	10
122	Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) \pm pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1003-1003.	0.8	8
123	Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1025-1025.	0.8	1
124	Sentinel lymph node biopsy using indocyanine green fluorescence navigation method after neoadjuvant chemotherapy for patients with clinically node-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12108-e12108.	0.8	0
125	Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 129.	2.2	85
126	Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. <i>Journal of Biomedical Optics</i> , 2016, 21, 116009.	1.4	48

#	ARTICLE	IF	CITATIONS
127	A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. <i>Experimental Cell Research</i> , 2016, 343, 177-189.	1.2	6
128	Genomic tumor evolution of breast cancer. <i>Breast Cancer</i> , 2016, 23, 4-11.	1.3	26
129	Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 44-50.	0.7	90
130	The effects of frozen gloves and socks on paclitaxel-induced peripheral neuropathy among patients with breast cancer: A self-controlled clinical trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10022-10022.	0.8	3
131	Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).. <i>Journal of Clinical Oncology</i> , 2016, 34, 599-599.	0.8	2
132	PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS636-TPS636.	0.8	0
133	Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1027-1027.	0.8	0
134	Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 593-593.	0.8	0
135	Data of a fluorescent imaging-based analysis of anti-cancer drug effects on three-dimensional cultures of breast cancer cells. <i>Data in Brief</i> , 2015, 5, 429-433.	0.5	1
136	Clinical Report on the First Prototype of a Photoacoustic Tomography System with Dual Illumination for Breast Cancer Imaging. <i>PLoS ONE</i> , 2015, 10, e0139113.	1.1	53
137	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 816-829.	5.1	261
138	Personalization of loco-regional care for primary breast cancer patients (part 2). <i>Future Oncology</i> , 2015, 11, 1301-1305.	1.1	3
139	Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. <i>Breast Cancer</i> , 2015, 22, 586-595.	1.3	19
140	An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 27-40.	1.9	8
141	Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 507-507.	0.8	55
142	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. <i>Journal of Clinical Oncology</i> , 2015, 33, 512-512.	0.8	8
143	Near infrared imaging using indocyanine green for sentinel lymph node biopsy in women with early breast cancer: Results of a meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12044-e12044.	0.8	1
144	MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locregionally recurrent or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS624-TPS624.	0.8	10

#	ARTICLE	IF	CITATIONS
145	RE: Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	1
146	A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. <i>Breast Cancer</i> , 2014, 21, 20-27.	1.3	13
147	Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS657-TPS657.	0.8	1
148	Comment and reply on: Vasohibin-1 and its emerging role in the evolution and progression of systemic tumors besides renal cell carcinomas. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 105-106.	1.5	1
149	Development of Photoacoustic Mammography for Detection of Breast Cancer. <i>Nippon Laser Igakkaishi</i> , 2013, 34, 24-29.	0.0	1
150	Breast MR Image Fusion by Deformable Implicit Polynomial (DIP). <i>IPSJ Transactions on Computer Vision and Applications</i> , 2013, 5, 99-103.	4.4	3
151	Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 919-926.	1.1	5
152	BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS648-TPS648.	0.8	8
153	Comprehensive analysis of serum N-glycans as a biomarker for breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21031-e21031.	0.8	0
154	Activation by zoledronic acid and IL-18 of $\gamma\delta$ T cells from early-stage breast cancer patients in the context of helper NK cells.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21004-e21004.	0.8	0
155	Effect of orally administered S-1 on circulating endothelial cells in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21052-e21052.	0.8	0
156	Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. <i>Cancer Science</i> , 2011, 102, 858-865.	1.7	44
157	Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference. <i>Annals of Surgical Oncology</i> , 2011, 18, 2885-2892.	0.7	8
158	Trends in breast cancer treatment: Focusing on tumor subtype-specific treatment. <i>Tenri Medical Bulletin</i> , 2011, 14, 1-25.	0.1	0
159	Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. <i>BMC Cancer</i> , 2010, 10, 56.	1.1	17
160	Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. <i>Cancer</i> , 2010, 116, 3112-3118.	2.0	104
161	The Breast Cancer Working Group Presentation was Divided into Three Sections: The Epidemiology, Pathology and Treatment of Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, i13-i18.	0.6	30
162	Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer. <i>Breast Cancer</i> , 2009, 16, 207-218.	1.3	6

#	ARTICLE	IF	CITATIONS
163	Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 531-539.	1.1	97
164	Lapatinib. <i>Drugs</i> , 2007, 67, 2109-2110.	4.9	0
165	Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. <i>International Journal of Oncology</i> , 2007, 31, 899-906.	1.4	7